A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections.
about
A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandardAnti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusionCorneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin)The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic reviewSingle-cell resolution imaging of retinal ganglion cell apoptosis in vivo using a cell-penetrating caspase-activatable peptide probeCost-effectiveness of treatment of diabetic macular edema.A safety study of high concentration and high frequency intravitreal injection of conbercept in rabbitsRanibizumab versus bevacizumab for ophthalmic diseases related to neovascularisation: a meta-analysis of randomised controlled trials.Comparative cyto-histological study of needle tip aspirates and entry sites after intravitreal injection using different needle types.Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).The Chinese medicine formula HB01 reduces choroidal neovascularization by regulating the expression of vascular endothelial growth factor.Melissa officinalis extract inhibits laser-induced choroidal neovascularization in a rat model.Safety and dosing of bevacizumab (avastin) for the treatment of recurrent respiratory papillomatosis.Targeted delivery of antiglaucoma drugs to the supraciliary space using microneedles.Current treatments in diabetic macular oedema: systematic review and meta-analysisAflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases.Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema.Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis)Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis.Pharmacokinetic evaluation of pegaptanib octasodium for the treatment of diabetic edema.Lasting controversy on ranibizumab and bevacizumab.Intraocular Pressure Changes in Non-Glaucomatous Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Agents.Insight into 144 patients with ocular vascular events during VEGF antagonist injectionsTargeted Intraceptor Nanoparticle for Neovascular Macular Degeneration: Preclinical Dose Optimization and Toxicology Assessment.Changes in the foveal microstructure after intravitreal bevacizumab application in patients with retinal vascular disease.A matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extractionPhotopsias during Systemic Bevacizumab TherapyEfficacy of Antibody Delivery to the Retina and Optic Nerve by Topical AdministrationTargeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain.Inhibition of pathological retinal neovascularization by semaphorin 3A.Sterile endophthalmitis after intravitreal injections.Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literatureReal-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario.Effects of intravitreally injected Fc fragment on rat eyes.Effect of Anti-vascular Endothelial Growth Factor Antibody on the Survival of Cultured Retinal Ganglion Cells.Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration.Unilateral branch retinal arterial occlusion following administration of bevacizumab for branch retinal vein occlusion.The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters.Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting.Effect of oral tranexamic acid on macular edema associated with retinal vein occlusion or diabetes.
P2860
Q21090878-5993740C-7B34-4AA3-AF69-29B34C30DD63Q24194783-9EB27553-E720-4DCD-BAF9-264EDE18845DQ26823757-A3EC8C22-9070-4DCF-9871-307FC7D5B2B6Q27013836-CABAB5AF-9F93-4EA4-8F90-2444D92B98FAQ27321716-17CE9631-990F-47CC-8C1F-379B78EF3525Q33606611-8DF2F956-FDE9-46E9-9AD9-8F2F49236002Q33674476-69800A5A-38C4-4357-9FEB-CEE329C6EEA5Q33830753-299803AA-B265-40FF-9B0C-59F412DF24E5Q33887880-0DD18858-3356-4D1E-AD85-FB620790B982Q34092454-68DDA6E3-7103-4BE6-8473-1867A72DB54EQ34296110-DF661216-0D2F-46A7-9166-ABF8A6B43F20Q34338680-7B42337B-A8F0-402B-BBAD-E13E60DAC0A3Q34421695-40B5B272-61C7-484E-B978-77A3619F196EQ34511234-45870954-EAD3-4438-BB60-D5BA434FB62FQ34606190-D587477F-63E5-4A54-865B-52D71564C521Q34658699-BB206BD4-9996-40C5-AB78-4AA5E3646A2DQ34758061-3F80921D-D38F-497C-9C83-B825195701BCQ35016867-395ABE82-5B56-4859-92AA-DF56D8EEAE2BQ35162123-E3527857-815A-4360-8BED-DAF4B1549592Q35173079-30060B50-3065-443F-B722-41CEFC4216A8Q35641933-40D86A3F-E569-461E-A2AD-7DFD31514268Q35770567-D914D6F8-F76C-4914-BFD4-B95DC4413F7EQ35822200-85A076EC-C931-4ADC-AD70-AAB96747045DQ36290649-A6A6B7EC-A9B4-4689-9FBB-C5AE94768D2FQ36555095-59EA1B70-8DF6-4AC8-97DC-E038FF6A9DB4Q36738575-C9C8385F-EE10-4937-85A0-3DE1D62E872AQ36741382-A0551784-36A3-4818-AE7F-5BDBE5F71F63Q36881990-CDD19491-CBC8-4AD0-8582-22EC4090C065Q36890872-E54E578D-B3DE-4DB1-8B5B-408CA44D2D9EQ36964256-552AFAAC-8AA3-48D0-B8B3-AA981A70B19CQ38042910-6A5D7753-81F2-40FD-BA1F-B15C60E769BCQ38110731-46BA4CE6-5C8B-4933-A1E3-192422359A26Q38671399-DA7D4FE8-5602-4DE0-8BCE-2DA6475D2EB9Q40502050-EF78776B-BF90-4DB4-B97A-F80141EB88D5Q41221841-64DCF3D9-3F34-4FA2-A0C9-A1ACE91D2AACQ41925040-EB260327-E415-46E1-BAF8-CFB31CF9C561Q44205884-B24C8423-C093-49AD-A985-CCDC761F3CA6Q44520157-6E2D260A-A6AD-4B88-ACB6-8B2A598454C5Q47918653-06526BC8-71F2-4554-BB81-F6CBACD99EE0Q49197963-CBDA2DA2-BDBF-4E92-8F4A-20363A29F24B
P2860
A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A systematic review of the adv ...... lial growth factor injections.
@ast
A systematic review of the adv ...... lial growth factor injections.
@en
type
label
A systematic review of the adv ...... lial growth factor injections.
@ast
A systematic review of the adv ...... lial growth factor injections.
@en
prefLabel
A systematic review of the adv ...... lial growth factor injections.
@ast
A systematic review of the adv ...... lial growth factor injections.
@en
P2093
P1433
P1476
A systematic review of the adv ...... lial growth factor injections.
@en
P2093
Ellen C La Heij
Fred Hendrikse
Jan S A G Schouten
Margriet I van der Reis
Peter J Ringens
Yvonne De Jong-Hesse
P304
P356
10.1097/IAE.0B013E3182278AB4
P577
2011-09-01T00:00:00Z